Titan Pharmaceuticals, Inc. Retained Earnings
Titan Pharmaceuticals, Inc. had Retained Earnings of -$397.79 million as of 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2025-08-14
- 2025-06-30: Retained Earnings (Accumulated Deficit) -$397.79M.
- 2025-03-31: Retained Earnings (Accumulated Deficit) -$397.10M.
- 2024-12-31: Retained Earnings (Accumulated Deficit) -$396.54M.
- 2024-09-30: Retained Earnings (Accumulated Deficit) -$395.75M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2025-06-30 | -$397.79M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | -$397.10M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | -$396.54M 10-Q · filed 2025-08-14 | |
| 2024-09-30 | -$395.75M 10-Q · filed 2025-01-03 | |
| 2024-06-30 | -$394.98M 10-Q · filed 2024-08-15 | |
| 2024-03-31 | -$392.89M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | -$391.83M 10-K · filed 2025-03-20 | |
| 2023-09-30 | -$390.27M 10-K · filed 2024-04-01 | -$389.86M 10-Q · filed 2023-11-14 |
| 2023-06-30 | -$389.52M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | -$387.94M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | -$386.26M 10-K · filed 2024-04-01 | |
| 2022-09-30 | -$383.69M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$381.06M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | -$378.60M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | -$376.06M 10-K · filed 2023-03-31 | |
| 2021-09-30 | -$373.51M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | -$371.60M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | -$369.92M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | -$367.28M 10-K · filed 2022-03-25 | |
| 2020-09-30 | -$364.19M 10-Q · filed 2020-11-16 | |
| 2020-06-30 | -$359.26M 10-Q · filed 2020-08-14 | |
| 2020-03-31 | -$354.62M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | -$349.04M 10-K · filed 2021-03-31 | |
| 2019-09-30 | -$345.10M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | -$342.29M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | -$337.10M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | -$332.58M 10-K · filed 2020-03-30 | |
| 2018-09-30 | -$329.07M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | -$326.75M 10-Q · filed 2018-08-14 | |
| 2018-03-31 | -$325.88M 10-Q · filed 2018-05-15 | |
| 2017-12-31 | -$323.27M 10-K/A · filed 2019-04-02 | |
| 2017-09-30 | -$319.61M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | -$315.42M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | -$311.97M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | -$308.96M 10-K · filed 2018-04-02 | |
| 2016-09-30 | -$306.64M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | -$304.02M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | -$315.94M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | -$314.10M 10-K · filed 2017-03-16 | |
| 2015-09-30 | -$311.81M 10-Q · filed 2015-11-16 | |
| 2015-06-30 | -$310.00M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | -$307.72M 10-Q · filed 2015-05-13 | |
| 2014-12-31 | -$302.82M 10-K · filed 2016-03-15 | |
| 2014-09-30 | -$302.35M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | -$303.06M 10-Q · filed 2014-08-13 | |
| 2014-03-31 | -$302.22M 10-Q · filed 2014-05-14 | |
| 2013-12-31 | -$300.42M 10-K · filed 2015-03-31 | |
| 2013-09-30 | -$300.21M 10-Q · filed 2013-11-14 | |
| 2013-06-30 | -$299.06M 10-Q · filed 2013-08-14 | |
| 2013-03-31 | -$304.13M 10-Q · filed 2013-05-15 | |
| 2012-12-31 | -$310.13M 10-K · filed 2014-03-31 | |
| 2012-09-30 | -$309.85M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | -$301.83M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | -$300.11M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | -$294.95M 10-K · filed 2013-03-18 | |
| 2011-09-30 | -$292.05M 10-Q · filed 2011-11-14 | |
| 2011-06-30 | -$291.25M 10-Q/A · filed 2011-08-17 | |
| 2010-12-31 | -$279.75M 10-K · filed 2012-03-15 |